8-K: Dentsply Sirona Reports Q2 2026 Results, Maintains Outlook

Dentsply Sirona announced second quarter 2026 financial results, reporting net sales of $898 million and adjusted EPS of $0.52, meeting expectations and reiterating its full-year outlook.

Summary

• Dentsply Sirona reported net sales of $898 million for the second quarter of 2026, a decrease of 4.1% compared to $936 million in the second quarter of 2025.
• GAAP gross margin improved to 54.9% from 52.4% year-over-year.
• GAAP diluted earnings per share was $0.18, compared to a loss of $0.22 in the prior year.
• Adjusted gross margin was 56.4%, and adjusted EBITDA margin was 21.3%.
• Adjusted diluted earnings per share (EPS) was $0.52, matching the prior year's adjusted EPS.
• The company repurchased 1.3 million shares of common stock for approximately $12 million during the quarter.
• Operating cash flow was $99 million, and free cash flow was $55 million, both significantly higher than the prior year.
• The company is maintaining its 2026 outlook for net sales between $3.5 billion and $3.6 billion, and adjusted EPS between $1.40 and $1.50.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, indicating stabilization and in-line performance with expectations, but without significant upside surprises.

Positives

• GAAP gross margin improved to 54.9% from 52.4% year-over-year.
• GAAP diluted earnings per share turned positive at $0.18 from a loss of $0.22 in Q2 2025.
• Operating cash flow increased to $99 million from $48 million in the prior year.
• Free cash flow significantly improved to $55 million from $16 million in the prior year.
• Expanded partnership with Medline Sinclair to broaden access to Connected Technology Solutions portfolio across Canada.
• Repurchased 1.3 million shares of common stock, demonstrating a commitment to shareholder returns.
• Maintained full-year 2026 outlook for net sales and adjusted EPS, indicating confidence in future performance.

Negatives

• Net sales decreased by 4.1% to $898 million compared to $936 million in the prior year.
• Constant currency sales decreased by 6.3%.
• Adjusted EBITDA decreased by 3.3% to $190 million from $197 million in the prior year.
• Net sales in the Americas region decreased by 10.7% (11.6% in constant currency).
• Net sales in the EMEA region decreased by 3.6% (in constant currency).
• Net sales in Orthodontic and Implant Solutions segment decreased by 14.9% (15.6% in constant currency).

Risks

• The company's forward-looking statements are subject to numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those described.
• These risks are detailed in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
• There is no assurance that any expectation, belief, goal, or plan set forth in any forward-looking statement can or will be achieved.
• The company does not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of the release.

Future Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

Management Comments

• "2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona.
• "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business."
• "Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company."
• "As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Industry Context

StockSavvy.ai notes that the dental technology and consumables market is competitive, with companies focusing on innovation, digital solutions, and market access. Dentsply Sirona's results reflect ongoing efforts to navigate market dynamics and execute strategic initiatives for growth.

Stakeholder Impact

• Shareholders: The reiteration of the 2026 outlook and improved cash flow may be viewed positively, while the net sales decline presents a challenge.
• Employees: The focus on realigning sales teams and reinvesting in the business suggests potential internal restructuring and strategic shifts.
• Distributors: The emphasis on strengthening and expanding distributor relationships indicates a focus on improving channel partnerships.

Next Steps

• Continue executing the Return-to-Growth Action Plan.
• Strengthen and expand distributor relationships.
• Realign sales teams.
• Reinvest in the business.
• Drive sustained, profitable growth through disciplined strategy execution.

Key Dates

Recommendation

The filing indicates stabilization and performance in line with expectations, with improved cash flow and maintained guidance. However, the continued decline in net sales and the absence of significant growth drivers suggest a 'hold' position until more robust signs of turnaround and growth emerge.

Keywords

dental products, medical devices, financial results, earnings per share, net sales, adjusted EBITDA, cash flow, share repurchase